NeoBase Succinylacetone Assay Solution, Product Number: 3042-0020; Affected UDI Numbers: (01)0643...

FDA Device Recall #Z-1692-2018 — Class II — November 2, 2017

Recall Summary

Recall Number Z-1692-2018
Classification Class II — Moderate risk
Date Initiated November 2, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm PerkinElmer Life and Analytical Sciences, Wallac, OY
Location Turku, N/A
Product Type Devices
Quantity 5275

Product Description

NeoBase Succinylacetone Assay Solution, Product Number: 3042-0020; Affected UDI Numbers: (01)06438147295708(17)180531(10)654184 (01)06438147295708(17)180531(10)653414 (01)06438147295708(17)180531(10)653657 (01)06438147295708(17)180630(10)654923 (01)06438147295708(17)180630(10)655680 (01)06438147295708(17)180630(10)655300 (01)06438147295708(17)180630(10)654924 (01)06438147295708(17)180831(10)656025 (01)06438147295708(17)180831(10)657055 (01)06438147295708(17)180831(10)656170 (01)06438147295708(17)180831(10)656320 (01)06438147295708(17)181031(10)657768 (01)06438147295708(17)181031(10)657513 (01)06438147295708(17)181031(10)658006

Reason for Recall

There is a potential for leaking vials for certain lot numbers where, if proper attire is not used as instructed, a transient minor allergic skin reaction may result when handling leaking succinylacetone reagent vials.

Distribution Pattern

Distributed in 20 US states: AL, AR, AZ, CA, CO, FL, GA, IL, IN, KS, KY, LA, MI, MO, NV, OH, OR, SC, TN, TX.

Lot / Code Information

Affected lots: 654184 653414 653657 654923 655680 655300 654924 656025 657055 656170 656320 657768 657513 658006

Other Recalls from PerkinElmer Life and Analytical Scien...

Recall # Classification Product Date
Z-1239-2019 Class II AutoDELFIA¿ hCG Kit, In Vitro Diagnostic for th... Jan 10, 2019
Z-1237-2019 Class II DELFIA¿ hCG Kit, In Vitro Diagnostic for the de... Jan 10, 2019
Z-1238-2019 Class II AutoDELFIA¿ hCG Kit, In Vitro Diagnostic for th... Jan 10, 2019
Z-1541-2018 Class II Specimen Gate Screening Center, Part Number 500... Nov 17, 2017
Z-1220-2018 Class III AutoDELFIA Neonatal immunoreactive trypsin(ogen... Sep 25, 2017

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.